Research Article| Volume 20, SUPPLEMENT 3, C45-C58, 1998

Developing a uniform reporting system for preventable adverse drug events

  • Diane D. Cousins
    Address correspondence to: Diane D. Cousins, RPh, Vice President for Practitioner Reporting Programs, United States Pharmacopeial Convention, Inc., 12601 Twinbrook Parkway, Rockville, MD 20852-1790.
    United States Pharmacopeial Convention, Inc., Rockville, Maryland U.S.A.
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.


      The United States Pharmacopeia (USP) Practitioners' Reporting Network utilized nearly three decades of experience to design and develop a nationwide, anonymous, Internet-accessible service for hospitals to report and benchmark medication errors (also known as “preventable adverse drug events”). As nationwide experiential reporting enters the 21st century, the features of MedMARx™ will provide facilities with the unprecedented ability to conduct daily continuous quality improvement that encompasses medication error risk analysis and prevention based on the experiences of other facilities. Data elements were developed based on review by expert panels and USP's experience with the Medication Errors Reporting Program. The success of this model could indicate its usefulness in other practice settings and for broader applications in health care.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bates DW
        • Cullen D
        • Laird N
        • et al.
        Incidence of adverse drug events and potential adverse drug events: Implications for prevention.
        JAMA. 1995; 274: 29-34